Lorenzo Esti, Federico Fattorini, Cosimo Cigolini, Stefano Gentileschi, Riccardo Terenzi, Linda Carli
{"title":"Clinical aspects of psoriatic arthritis: one year in review 2024.","authors":"Lorenzo Esti, Federico Fattorini, Cosimo Cigolini, Stefano Gentileschi, Riccardo Terenzi, Linda Carli","doi":"10.55563/clinexprheumatol/7gug1a","DOIUrl":null,"url":null,"abstract":"<p><p>Psoriatic arthritis is a very pleomorphic inflammatory disease characterised by its association with psoriasis and the development of a wide spectrum of comorbidities that can impact patients' prognosis and quality of life.In recent years, several new drugs have been developed, showing significant efficacy in alleviating symptoms and signs, while maintaining a generally favourable safety profile. Despite these advancements, the management of PsA remains potentially suboptimal. Indeed, a percentage of patients do not respond to therapies, or they may improve only in limited outcomes, resulting in a challenge for the management of the burden of disease.In this paper we reviewed the literature on PsA from January 1st 2022 to July 1st 2024.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":"43 1","pages":"4-13"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.55563/clinexprheumatol/7gug1a","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Psoriatic arthritis is a very pleomorphic inflammatory disease characterised by its association with psoriasis and the development of a wide spectrum of comorbidities that can impact patients' prognosis and quality of life.In recent years, several new drugs have been developed, showing significant efficacy in alleviating symptoms and signs, while maintaining a generally favourable safety profile. Despite these advancements, the management of PsA remains potentially suboptimal. Indeed, a percentage of patients do not respond to therapies, or they may improve only in limited outcomes, resulting in a challenge for the management of the burden of disease.In this paper we reviewed the literature on PsA from January 1st 2022 to July 1st 2024.
期刊介绍:
Clinical and Experimental Rheumatology is a bi-monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983.